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Stage classification and predicting prognosis are integral facets of cancer care. Clinicians often lament that the 
stage classification system falls short in predicting progno-
sis, and suggest that the classification system should include 
other prognostic factors. It is germane to explore these issues 
because work on revisions of the stage classification system 
are currently underway. This article reflects on the nature of 
classification and prognostication to contribute to our collec-
tive thinking.
The Task of The Bean CounTer
“Make everything as simple as possible, but not sim-
pler,” Albert Einstein
The nature of Classification
What is stage classification? Fundamentally, it is a 
description of the anatomic extent of a cancer, involving clear 
definitions to consistently categorize a patient’s tumor. Stage 
classification is inherently concrete, designed to apply to an 
individual, and to consistently produce the same stage assign-
ment, given the same staging information.
Nevertheless, change is constant. New imaging and 
biopsy procedures add to the available information but do not 
affect the definition of tumor, node, metastasis (TNM) classes 
or stages. More importantly, more data uncover nuances lead-
ing to greater complexity. Periodic revision of stage classifica-
tion system is needed. However, the importance of consistency 
dictates that changes occur only occasionally in a well defined, 
formal manner.
Stage classification is like the work of an accoun-
tant, who reviews an individual business’s financial records. 
Transactions are assigned to particular categories, which must 
be consistent and universally accepted. As new types of trans-
actions are developed, new standards are defined periodically, 
maintaining universal consistency.
Other classifications also apply (e.g., histologic type, 
genetic mutations, or the patient’s performance status). 
However, although these are useful, they do not per se affect 
the anatomic extent of disease. Similarly, other accounting 
classifications (e.g., a bond rating) are important, but do not 
alter where a specific transaction is placed on the financial 
balance sheet.
uses of a stage Classification system
Primarily, stage classification provides a consistent 
means of communication, allowing us to speak clearly to 
one another about an individual tumor or a group of tumors. 
The anatomic extent of disease is also a major factor affect-
ing prognosis, but prognosis is affected by many other factors 
(e.g., the treatment given, tumor type, comorbidities).
The anatomic extent of disease is helpful in selecting a 
treatment approach, along with other factors (e.g., comorbidi-
ties, logistics, and patients’ preferences). However, the role of 
a particular treatment is defined by data from clinical trials; 
the stage classification only provides an ability to communi-
cate and apply a clinical trial’s results.
how should we Define stage Classification?
Where should we draw the lines between TNM classes 
and stage groups? Initial definitions were largely empiric, but 
we need a system that can be applied consistently. Ideally, we 
should segregate tumors into groups with similar biologic 
behavior; patients in these groups would likely remain coher-
ent even as treatments evolve, and the prognosis changes. But 
how do we define biologic behavior? Can this be determined 
by the anatomic extent at diagnosis? Is the biologic behav-
ior relatively stable over time, or does this evolve (e.g., from 
indolent, to locally invasive, to capable of metastasizing)? 
Unfortunately, we have little knowledge to guide us in answer-
ing these questions.
Should we abandon anatomic features, and define tumor 
biology from genetic characteristics? Our understanding 
of how genetic changes influence biologic behavior is 
rudimentary, centered primarily on specific mutations that 
predict response to a particular targeted treatment. We know 
little about how genetic changes affect actual biologic behavior 
over the course of the disease. The recent study, showing that 
acquired resistance of lung cancers to an epidermal growth 
factor receptor inhibitor is because of transformation of 
adenocarcinoma into small-cell lung cancer in a substantial 
proportion of patients, should make us realize how little we 
really know about tumor biology.1
Only natural history (observation without any active 
treatment) allows actual assessment of tumor biology; this 
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is available in only a few patients (with severe comorbidi-
ties), who are not representative of the general population of 
patients. Actual natural history studies are not ethical and are 
therefore unattainable.
Can the prognosis of patients in general (who are being 
treated in various ways) serve as a surrogate for natural his-
tory and provide clues about biologic behavior? This approach 
was used in recent revisions of the stage classification sys-
tem. However, in the International Association for the Study 
of Lung Cancer database, the 5-year survival of patients with 
the same anatomic extent of disease, varied markedly depend-
ing on geographic region, type of source data, and other fac-
tors, likely reflecting that the observed prognosis is perhaps 
determined less by the inherent tumor biology than factors, 
such as the treatment given and the effectiveness thereof, 
socioeconomic factors, and comorbidities. This problem was 
addressed (indirectly) during the development of the 7th edi-
tion of the lung cancer stage classification by requiring that 
TNM classes and stage groups be separated not by their actual 
prognosis (which was highly variable), but by differences in 
prognosis that were consistent within multiple subgroup 
analyses (regions, histologic type, clinical/pathologic etc.).2 
Unfortunately, this approach doesn’t actually eliminate or cor-
rect for confounding factors. Thus, observed outcomes reflect 
many factors (primarily not related to the anatomic disease 
extent), and should not be confused with the natural history 
of the disease.
sPeCuLaTors, GaMBLers, anD  
forTune TeLLers
“It is difficult to make predictions, especially about the 
future.”
Winston Churchill
Once cancer is diagnosed, we immediately want to pre-
dict the prognosis. This is undeniably a major clinical need. 
In developing ways to do this, it is helpful to reflect on the 
fundamental nature of this process.
Prediction of prognosis is inherently multifactorial and 
complex (Fig. 1). Cancer often becomes a dominant issue 
affecting lifespan, but there are still many things at play 
(e.g., disease extent, comorbidities, and treatment decisions). 
Furthermore, the role various factors play depends on the 
situation. A particular comorbidity may have an impact for 
one particular treatment but not for another. A mutation may 
be critical for treatment with a targeted agent, but have little 
importance otherwise.
Prognostication is inherently associated with a degree of 
uncertainty. The future is impacted by many factors in a com-
plex manner, including unpredictable random new events. The 
number of prognostic factors we have not yet identified likely 
far exceeds those we know about. We have focused on express-
ing what we know, but we need tools to describe the uncertainty 
of the prediction, and to what extent outcomes are determined 
by known prognostic factors versus unknown factors.
Prognostic data fundamentally apply to a population of 
patients. In a large population, other known and unknown fac-
tors will likely approach a general mean and be similar to the 
population the prognostic model is derived from. However, we 
want to predict prognosis for an individual patient. At least theo-
retically, one might be able to predict individual prognosis by 
including enough factors, but this is inherently associated with 
ever greater uncertainty. At the level of an individual, a person-
alized prediction of prognosis would likely be associated with 
such a wide confidence interval that the prediction is of little use.
Prognostication is also an inherently fluid process. As 
soon as an estimate of prognosis is available, clinicians start 
trying to improve the outcome. Thus, the estimate of prognosis 
for a specific individual will likely be different 2 years from 
now, than it is for the same individual today. Furthermore, this 
specific individual’s prognosis changes as the course of the 
disease and treatment unfold and other events occur.
Prognostication is inherently prone to biases and self-
fulfilling prophecies. If we are convinced of a grim outlook 
and only institute end-of-life measures, we may never realize 
what the outlook would be if treatment was given.
Thus, prognostication is quite different than stage clas-
sification. It is complex and dependent on multiple factors, 
including many that are unknown or unpredictable. It is fluid, 
constantly changing, and inherently associated with uncer-
tainly. It is designed to apply to a population of patients, which 
is not how we want to use it. Prognosis cannot be defined at 
intervals by a carefully worded document, which establishes a 
standard; it is inherently a guess about the future.
The activity of prognostication is much more akin to 
that of a speculator or gambler. It involves the future, which 
is inherently somewhat unpredictable. It is fluid, affected 
by many factors, analogous to interest rates, supply and 
demand, or the opponents one is facing at the poker table. It is 
constantly evolving, much like a stock speculator affected by 
market fluctuations, or a gambler by each card played.
DIsCussIon
Classification and prognostication are inherently dif-
ferent. Keeping these separate maximizes the effectiveness 
fIGure 1.  Classification of prognostic factors from 
Gospodarowicz et al.3
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of each. Stage classification must be consistent and can be 
updated periodically. Prediction of prognosis is complex, mul-
tifactorial, and is constantly changing.
Stage classification should describe the anatomic extent 
of disease only. Other classifications and characteristics of the 
patient and tumor are important, but mixing these together 
makes the system overly complex, and only obscures much of 
what each classification can provide.
It is reasonable to use prognosis (even better consis-
tent differences in prognosis among various subgroups) to 
determine how to separate TNM classes and stage groups. 
However, prognosis is not providing insight into the tumor 
biology. It is highly confounded, perhaps, mostly by the treat-
ment given. Accounting for treatment provides a slightly 
better assessment (e.g., pathologic stage after r0 resection), 
but still leaves many factors unaddressed. Furthermore, 
stage classification must be practical; overemphasis of (con-
founded) statistical findings risks making the system too 
illogical and difficult to use.
A system to determine prognosis is clearly needed. This 
should present what is known and how much of the outcome is 
unexplained by known prognostic factors. It should also depict 
the degree of uncertainly, especially when applied to individ-
ual patients. The system should be reasonably validated, yet 
flexible enough to accommodate emerging new factors.
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